ClinicalTrials.gg
Sign In
RecruitingNCT06729840Updated Dec 11, 2024

Intralesional Treatment of Keloids

A Phase 3 interventional study of Injection in Scar, Hypertrophic, sponsored by Sohag University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-11.

Sponsored by Sohag University · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
Phase
Phase 3
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Intralesional injection in treatment of keloid

Read the detailed description

Our study will include 45 patient diveded into three groups , follow up will done before each session , 3month after the last session using photographing assessment , scoring , dermoscope

02

Conditions studied

  • Scar, Hypertrophic

Keywords

  • keloids , vitamin D
03

In context

Cicatrix, Hypertrophic

129 studies on the registry are indexed under Cicatrix, Hypertrophic; 31 are open to participants now.

This study's planned enrollment of 45 is above the median of 36 across 106 interventional studies indexed under Cicatrix, Hypertrophic.

Browse Cicatrix, Hypertrophic studies →

Lead sponsor

Sohag University is the lead sponsor of 1,230 studies on the registry; 636 are open to participants now.

Browse Sohag University studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Both sex aged 18-60 having keloid

Exclusion criteria

-

Exclusion Criteria:

  • pregnancy , lactation Skin disease
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
45 participants (estimated)

Study arms

  • Active comparator
    Group 1

    Will include 15 patients will injected with vitamin D

    Drug: Injection

  • Active comparator
    Group 2

    Will include 15 patients will injected with botulinum toxin type A

    Drug: Injection

  • Active comparator
    Group 3

    Will include 15 patients will injected with triamcinolone acetonide

    Drug: Injection

Interventions

  • DrugInjection

    Vitamin D , botox , tramcinolone intralesionally injected in keloid

06

What researchers measure

Primary outcomes

  1. Posas score

    patient and observer parameters will be assessed

    Time frame: One session every two weeks total duration 3 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2024; primary completion for Apr 2025, 4 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2024
First posted
Dec 11, 2024
StartEst.
Dec 1, 2024
Primary completionEst.
Apr 1, 2025
CompletionEst.
May 2, 2025
Last update
Dec 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06729840
Lead sponsor
Sohag University
Responsible party
Sama Alaaeldin Ahmed (Sohag, Sohag University) — Principal investigator
First posted
Dec 11, 2024
Start date
Dec 1, 2024 (estimated)
Primary completion
Apr 1, 2025 (estimated)
Completion
May 2, 2025 (estimated)
Last update
Dec 11, 2024

Study contacts

sama alaa, resident doctor
Contact
samaalaa.867@gmail.com
01027748791

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Cicatrix, Hypertrophic →

Other studies from this sponsor

Sohag University →

Start the discussion